One widely used approach is to switch to other classes of biologic agents that modulate different immune pathways, such as IL-6 receptor inhibitors such as tocilizumab, which are often used in rheumatoid arthritis, or IL-12/23 and IL-17 inhibitors, which play a significant role in the treatment of psoriasis, psoriatic arthritis, and Crohn’s disease in cases where anti-TNF therapy has proven ineffective [96,116,117,118]. Here, TNF is linked to psoriasis.